TrialESMO open2026

Durvalumab combined with weekly carboplatin/paclitaxel as first-line treatment of patients with recurrent and/or metastatic HNSCC not eligible for cisplatin-based chemotherapies: results of the multicenter prospective study FRAIL-IMMUNE.

J Fayette et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.